


06-25-01

Attorney Docket No.: C1039/7052(AWS)

A
Seq

06/22/01



USPTO

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No. C1039/7052(AWS)	
	First Named Inventor or Application Identifier	
	WEINER, George	
	Express Mail Label No.	EL844513663US
	Date of Deposit	June 22, 2001

USPTO

09/888320



06/22/01

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents</i>	ADDRESS TO: Box Patent Application Commissioner for Patents Washington, DC 20231
1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i> 2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> Statement filed in prior application, status still proper and desired. 3. <input checked="" type="checkbox"/> Specification - Total pages 88 77 - pages description 1 - pages abstract 10 - pages claims 77 - Total claims 4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) 6 - Total sheets <input checked="" type="checkbox"/> Informal <input type="checkbox"/> Formal 6 - Total drawings 5. <input type="checkbox"/> Oath or Declaration - Total pages a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i> <i>[Note Box 6 below]</i> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. <input type="checkbox"/> Incorporation by Reference <i>(usable if Box 5b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 19. 7. <input checked="" type="checkbox"/> Application Data Sheet, See 37 CFR 1.76	8. <input type="checkbox"/> CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix) 9. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Form (CRF) b. <input checked="" type="checkbox"/> Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input checked="" type="checkbox"/> paper (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS 10. <input type="checkbox"/> Assignment Papers/cover sheet & documents(s) 11. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney 12. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i> 13. <input type="checkbox"/> Information Disclosure Statement/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 14. <input type="checkbox"/> Preliminary Amendment 15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 16. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 17. <input type="checkbox"/> Request and Certification Under 35 U.S.C. §122(b)(2)(B)(ii) 18. <input type="checkbox"/> Other: _____ _____

19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____, filed on _____, entitled _____ and now _____.

☐ Cancel in this application claims _____ before calculating the filing fee.

☐ Amend the specification by inserting before the first line of the specification on page 1, after the title, the following:

--This application is a ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____, filed on _____, entitled _____ and now _____.--

Prior application information: Examiner _____ Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

20. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER:



23628

OR

ATTORNEY'S NAME	Alan W. Steele, Reg. No. 45,128				
FIRM NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	Alan W. Steele, Reg. No. 45,128
SIGNATURE	
DATE	June 22, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : Unknown
Filing Date : Herewith
Applicant(s) : George Weiner and Gunther Hartmann
Title : METHODS FOR ENHANCING ANTIBODY-INDUCED
CELL LYSIS AND TREATING CANCER


Commissioner for Patents
Washington, DC 20231

Sir:

STATEMENT UNDER 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f) regarding nucleotide and/or amino acid sequence disclosures in patent applications, Applicant's attorney avers that the paper copy of the "sequence listing" and the computer readable form required by §1.821 are the same.

Respectfully submitted,



Alan W. Steele
Reg. No.: 45,128
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
United States of America
Telephone: 617-720-3500
Facsimile: 617-720-2441

DOCKET NO.: C1039/7052 (AWS)
DATE: June 22, 2001